Pfizer (NYSE:PFE) inks a letter of intent with BioNTech SE (NASDAQ:BNTX)
aimed at co-developing and distributing (excluding China) an mRNA-based
vaccine against COVID-19 infection. The parties have executed a
Material Transfer and Collaboration Agreement enabling the collaborative
work to begin.
The focus of the partnership, originally formed in
2018 to develop mRNA-based vaccines for preventing the flu, will be to
accelerate development of BioNTech’s COVID-19 vaccine program BNT162,
expected to enter the clinic by the end of next month.
Financial terms and additional details pertaining
to development, manufacturing and commercialization will be finalized
over the next several weeks.
https://seekingalpha.com/news/3552377-pfizer-teams-up-biontech-to-develop-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.